Turnbull A C, Rees M C
Nuffield Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Headington, Oxford.
Br J Obstet Gynaecol. 1990 Aug;97(8):713-5. doi: 10.1111/j.1471-0528.1990.tb16244.x.
The role of gestrinone, 2.5 mg twice weekly, in treating proven menorrhagia (greater than 80 ml) was examined in 19 women. They were treated for five cycles (2 placebo, 3 active), taking one capsule twice weekly. Placebo had no effect on menstrual blood loss (MBL). On gestrinone 10 women became amenorrhoeic, in five MBL was markedly reduced (5-74 ml) and four did not respond. In three of the non-responders submucous leiomyomas were found at subsequent hysterectomy. Follow-up periods showed a persistent reduction in MBL for nine women in the first post-treatment menstruation.
对19名女性进行了研究，以考察每周两次服用2.5毫克孕三烯酮治疗确诊的月经过多（经量大于80毫升）的效果。她们接受了五个周期的治疗（2个安慰剂周期，3个活性药物周期），每周两次服用一粒胶囊。安慰剂对月经失血量（MBL）没有影响。服用孕三烯酮后，10名女性闭经，5名女性的MBL显著减少（5 - 74毫升），4名女性无反应。在3名无反应者中，后续子宫切除时发现了黏膜下肌瘤。随访期显示，9名女性在治疗后的首次月经中MBL持续减少。
